# A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

> **NCT04821687** · PHASE4 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 169 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ongentys 50mg
- **DRUG:** Madopar Tab. 125 or Perkin Tab. 25-100mg

## Key facts

- **NCT ID:** NCT04821687
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-17
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04821687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04821687, "A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04821687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*